CSTL Stock Analysis: Buy, Sell, or Hold?
CSTL - Castle Biosciences, Inc. Common Stock
$21.84
0.64 (3.02%)
▲
5d:
+5.71%
30d:
+6.33%
90d:
-15.18%
BUY
MODERATE Confidence
Analysis Updated: Jun 22, 2026 12:00 AM ET
Earnings: Aug 03, 2026
Get Alerted When CSTL Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: CSTL shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: CSTL shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: CSTL is currently trading at $21.84, which is considered extended relative to its 30-day fair value range of $19.83 to $21.37.
Technical Outlook: Technically, CSTL is in a strong downtrend. The price is approaching resistance at $21.52. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 3.0% recently.
Market Sentiment: CSTL has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $44.00 (+107.5%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, CSTL is in a strong downtrend. The price is approaching resistance at $21.52. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 3.0% recently.
Market Sentiment: CSTL has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $44.00 (+107.5%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$19.83 -
$21.37
Company Quality Score
56/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
68.4%
All Signals
- BEARISH: Price extended above range
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+3.0%)
- BULLISH: Trading 107.5% below Wall St target ($44.00)
Trading Range Analysis
30-Day Trading Range
$19.83 -
$21.37
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$19.86
Resistance Level
$21.52
Current Trend
Strong Downtrend
Technical data as of
Jun 22, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-22.80
Wall Street Target
$44.00
(+107.5%)
Revenue Growth (YoY)
-4.9%
Earnings Growth (YoY)
-51.6%
Profit Margin
-3.8%
Share & Embed Analysis
Last updated: June 23, 2026 10:40 AM ET
Data refreshes hourly during market hours. Next update: 11:40 AM
Data refreshes hourly during market hours. Next update: 11:40 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CSTL showing a specific setup today?
Insider Activity (6 Months)
0
Buys
15
Sells
Net
INSIDERS SELLING
Recent Transactions
Derek J Maetzold
SELL
3622 shares
2026-04-21
Derek J Maetzold
SELL
550 shares
2026-04-21
Derek J Maetzold
SELL
6214 shares
2026-04-06
Top Rated Diagnostics & Research Stocks
Top-rated stocks in Diagnostics & Research by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
TMO
Thermo Fisher Scientific… |
STRONG BUY
31 analysts |
$599 | 55 HOLD |
|
EXAS
EXACT Sciences Corporati… |
STRONG BUY
26 analysts |
$106 | 65 BUY |
|
GH
Guardant Health Inc |
STRONG BUY
23 analysts |
$142 | 56 HOLD |
|
DHR
Danaher Corporation |
STRONG BUY
25 analysts |
$242 | 51 HOLD |
|
NTRA
Natera Inc |
STRONG BUY
21 analysts |
$260 | 62 BUY |
